Phase 3 investment decisions for rare disease assets represent tens of millions in committed capital. Yet most pharmaceutical companies make these decisions with limited pricing intelligence, relying on internal estimates, waiting months for payer research, or proceeding without evidence-based forecasts at all.
The challenge is fundamental: traditional pricing methods require direct market comparators. But orphan drugs often treat conditions where nothing exists on the market.
This article explores why traditional approaches fail for rare disease pricing, how analogue benchmarking methodology solves this challenge, and what pharmaceutical companies gain from evidence-based pre-launch intelligence.
The orphan drug pricing challenge
Traditional methods need comparators that don’t exist
Comparator-based pricing is the pharmaceutical industry standard. You identify similar drugs in the same therapeutic area, analyse their pricing and market access outcomes, and use that competitive context to establish your own pricing strategy.
This works well for established therapeutic categories. Cardiovascular disease, diabetes, oncology, these markets have approved treatments providing clear benchmarks.
But rare diseases present a different challenge.
- No standard of care exists. Many orphan drugs are first-in-class treatments for conditions that previously had no approved therapies. You can’t benchmark against products that don’t exist.
- Small patient populations. Demonstrating clinical evidence with limited sample sizes creates uncertainty for payers who are accustomed to large-scale trials.
- Difficult trial methodology. Double-blind trials are often impractical in rare disease settings, raising payer questions about evidence quality.
- Limited longitudinal data. Long-term outcomes are unknown at launch, particularly for gene therapies and other potentially “curative” treatments.
Traditional pricing methods struggle in this context because they fundamentally require comparative context that doesn’t exist.
The timing problem
Even if you’re willing to wait for competitors to launch and provide comparative context, timing doesn’t work in your favour.
- Phase 3 investment decisions happen before competitive context exists. You need to commit resources to clinical development while pricing potential is still uncertain.
- Payer research takes 6 months or more. Traditional approaches involve extensive interviews, conjoint studies, and primary research. Board timelines don’t accommodate this.
- Internal estimates lack defensibility. Without evidence-based methodology, pricing forecasts are essentially educated guesses that are difficult to justify to executives and investors.
This creates a strategic gap: you need robust pricing intelligence at exactly the point in development where traditional methods can’t deliver it.
How Analogue Benchmarking solves this
The core principle: similar value drivers, not identical indications
Analogue benchmarking replaces the requirement for direct market comparators with a different approach: identify products with similar value drivers.
Instead of asking “which drugs treat the same condition,” we ask:
- Which orphan drugs have similar patient population sizes?
- Which diseases share comparable severity and unmet need profiles?
- Which clinical endpoints are analogous to your asset’s profile?
Example: An orphan drug for a rare metabolic condition has no direct comparators. But it shares value characteristics with other rare metabolic conditions, other genetic disorders requiring chronic treatment, and other assets targeting similar patient population sizes.
By identifying analogues across these dimensions rather than requiring identical indications, we create a basis for comparison even when traditional comparators don’t exist.
The methodology: payer-validated value frameworks
Analogue benchmarking isn’t just about finding similar drugs. It’s about understanding what payers actually value when making pricing and reimbursement decisions.
Step 1: Build market-specific value frameworks
GPI analysed HTA assessments from major payer organisations (for example, G-BA in Germany, HAS in France, NICE in the UK) to understand which factors drive their decision-making.
We identified 20-30+ clinical and commercial endpoints that payers assess across four key domains, including:
Burden & unmet need:
- Disease severity and mortality
- Patient population size
- Availability of alternatives
- Impact on quality of life
Product characteristics:
- Innovation status (first-in-class vs follow-on)
- Mechanism of action novelty
- Administration route and convenience
- Treatment durability
Trial design:
- Study phase and methodology quality
- Sample size and statistical power
- Appropriateness of comparator
- Length of follow-up
Clinical benefit:
- Efficacy (survival benefit, symptom improvement, functional outcomes)
- Safety profile and side effect severity
- Quality of life impacts
- Treatment durability
Step 2: Weight endpoints by market
Critically, payers in different markets prioritise these factors differently.
Payer priorities vary by market:
Payer priorities vary significantly by market. France, Germany, and UK each weight different factors when assessing orphan drugs, from clinical endpoints to trial methodology to health economic impact. Understanding these market-specific frameworks is critical for optimising launch strategy.
This market-specific weighting is essential. Generic pricing forecasts that assume payers value the same things across geographies systematically miss market dynamics.
Step 3: Score your asset
Using these frameworks, we assess your orphan drug across all relevant endpoints and generate a value score.
This isn’t subjective evaluation, it’s based on the same criteria payers document in HTA assessments.
Step 4: Identify analogues and predict pricing
With your asset’s value score established, we identify analogues (—products with similar scores across relevant dimensions) and analyse their pricing outcomes.
Because we know the value score and actual pricing for these analogues, we can predict pricing for your asset based on its relative value position.
What this enables
Pre-launch intelligence when strategic decisions still have flexibility
The value of analogue benchmarking isn’t just accuracy; it’s timing.
Traditional payer research: Comprehensive but can take over 4 months. By the time results arrive, clinical development decisions are locked in.
Internal estimates: Rapid but lack robustness. Difficult to justify to boards making high-stakes investment decisions.
Analogue benchmarking: Rapid + robust. Evidence-based forecasts delivered in days or weeks, not months. This is the critical difference.
Answering three strategic questions
Before committing to Phase 3, pharmaceutical companies need answers to three questions:
1. Will I be successful? (Market access feasibility assessment)
Value scoring shows which target markets present favourable payer dynamics based on your asset’s value profile. Not just “can we get reimbursed?” but “which markets weight our strengths favourably, and what evidence gaps need to be addressed?”
2. Will I get a good price? (Pricing potential by market)
Evidence-based pricing forecast showing pricing corridor relative to analogues. Not just “what’s the price point?” but “what’s driving that price, what’s limiting it, and what variables can we still influence?”
3. Which country should I launch in? (Optimal sequencing)
Market prioritisation based on value driver alignment, identify where your asset’s clinical and commercial profile matches payer priorities. Not just “where are the biggest markets?” but “where will payers value what we’ve built?”
The story behind the number
One of the most common questions we hear from rare disease teams: “Why do we need more than just a price point?”
Answer: Boards need justification, not just numbers. That’s what enables confident Phase 3 decisions, transparent understanding of what’s driving value, what’s limiting pricing power, and which markets align with your asset’s strengths.
This is “the story behind the number”, evidence-based justification that supports board presentations and strategic planning.
Purpose-built for orphan drug launches
Horizon’s analogue benchmarking platform is specifically designed for the unique positioning of orphan drugs: scenarios where nothing exists on the market.
Traditional pricing platforms and consultancies are designed for comparator-rich therapeutic categories. When adapted to rare diseases, they struggle because their fundamental assumptions don’t hold.
Analogue benchmarking was purpose-built for scenarios where direct comparators don’t exist. It’s not a workaround, it’s the methodology.
Comprehensive market coverage:
- EU4, UK, US (comprehensive orphan drug coverage)
- Additional markets available through consulting approach
Platform + consulting flexibility:
- Platform for rapid assessment using proven methodology
- Consulting expertise adds depth when complexity requires customised scenarios
Multiple use cases beyond single price points
Horizon isn’t just a pricing calculator. It’s a strategic intelligence platform for rare disease portfolio decisions.
Portfolio prioritisation
Which assets justify Phase 2/3 investment? Compare value scores across your pipeline using the same payer criteria. Evidence-based prioritisation showing which assets have highest pricing potential in target markets.
Launch country selection
Identify markets where payers weight your asset’s strengths favourably before committing resources. Launch strategy optimised for markets where clinical profile aligns with payer priorities.
Clinical development optimisation
Understand which endpoints drive pricing power in target markets before trial design is locked in. Scenario modelling tests value impact of different evidence packages.
Board presentations
Evidence-based justification with transparent methodology, the story behind the number that boards need to approve Phase 3 investment.
Competitive benchmarking
Generate competitor prices for context, understand first-to-market dynamics, inform strategic positioning.
Rapid + robust (not either/or)
One of the most common objections to evidence-based pricing forecasting: “We don’t have time for this level of analysis.”
The assumption is that depth requires time. That comprehensive methodology means months-long engagements.
GPI’s platform-led approach challenges this:
Rapid: Results in days or weeks, not months. Platform delivers standardised analysis using proven methodology.
Robust: Evidence-based forecasts with proven accuracy. Not sacrificing quality for speed; delivering both.
This matters because rare disease teams operate under compressed timelines. Board deadlines don’t wait for 6-month payer research projects.
The alternative shouldn’t be choosing between speed and quality. It should be having both.
Conclusion
Phase 3 investment decisions for orphan drugs represent significant capital commitment in contexts of high uncertainty.
Traditional pricing methods fail in these scenarios because they fundamentally require comparative context that doesn’t exist. Waiting for competitors to launch means making clinical development decisions without the pricing intelligence that should inform them.
Analogue benchmarking solves this by replacing the requirement for direct market comparators with proven methodology for assessing value based on similar drivers.
The result:
- Evidence-based forecasts delivered while strategic decisions still have flexibility
- Market-specific intelligence showing where asset strengths align with payer priorities
- The story behind the number, comprehensive justification for Phase 3 investment
- Rapid + robust (not either/or)
Global pharma companies use GPI’s analogue benchmarking because rare disease portfolio decisions demand evidence, not assumptions.
If your organisation is making Phase 3 investment decisions for orphan drug assets without evidence-based pricing forecasts, you’re operating with unnecessary risk.
The methodology exists. The accuracy is proven. The question is whether you’re using it.
Request demo to learn more about analogue benchmarking for rare disease pricing
Request a demo to explore GPI’s Horizon platform for orphan drug launches.
Download our case study showing proven accuracy,
